GS5885

MOQ : 50g 2400USD

Treatment of liver disease Ledipasvir (GS-5885) skype:aimee1924

Product Name: Ledipasvir (GS-5885)

Ledipasvir Synonyms: GS 5885;GS5885;GS-5885;Ledipasvir;GS-5885/Ledipasvir;gs-5885/gs5885;Ledipasvir / GS 5885;GS 588

Ledipasvir CAS: 1256388-51-8

Ledipasvir MF: C49H54F2N8O6

Ledipasvir Molecular Weight: 889.0

Ledipasvir Product Categories: API

Ledipasvir Categories: NS5A inhibitors;Fluorenes;Carbamates;Benzimidazoles;Cyclopropanes;Imidazoles;Breakthrough therapy

Ledipasvir Purity : 98%

Ledipasvir Solubility DMSO

Ledipasvir Storage at -20°C

Ledipasvir Appearance : White powders

Ledipasvir Package : 50g/foil bag

Ledipasvir Usage : Ledipasvir is most commonly used in combination with sofosbuvir for treatment in chronic hepatitis C genotype 1 patients.

This drug has been tested and shown efficacy in treatment-naive and treatment experienced patients.

Ledipasvir Product Description :

Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.

Ledipasvir is an inhibitor of the hepatitis C virus NS5A protein.

Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the nucleotide analog inhibitor sofosbuvir, ledipasvir, and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1.The sofosbuvir/ledipasvir coformulation is being tested with and without ribavirin. In February 2014 Gilead has filed for United States Food and Drug Administration (FDA) approval of ledipasvir/sofosbuvir oral treatment, without interferon and ribavirin.

On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg/sofosbuvir 400 mg called Harvoni.